Zantac linked to Cancer
- Pediatric (cancer of a child),
- Multiple Myeloma,
- Non-Hodgkins Lymphoma
Cancer Causing Agent NDMA
NDMA is used in gasoline and rocket fuel and other petroleum-based products. NDMA levels in Zantac may be 3,000 to 26,000 times higher than allowed levels set by the FDA. Investigations have uncovered links of at least 60 days of regular use of Zantac (ranitidine) with a diagnosis of cancer.
On April 16, 2020, the FDA alerted patients and health care professionals to Amneal Pharmaceutical’s voluntary recall of nizatidine oral solution (15 mg/mL). FDA Requests Removal of All and issued FAQs to their website: NDMA impurities in ranitidine .
If you were diagnosed with Cancer of the Stomach, Bladder, Kidney, Pancreas, Intestinal/Colorectal, Brain, Liver, Esophagus, Pediatric (cancer of a child), Leukemia/Blood, Multiple Myeloma or Non-Hodgkins Lymphoma after taking Zantac over-the-counter or prescription for regular use at least 60 days, contact us at 1-800-814-4540 or email firstname.lastname@example.org or fill out the contact form on the side bar. Our medical legal consultations are free and confidential.
Zantac MDL Created
The Zantac litigation has been created in the Southern District of Florida MDL Transfer Order before U.S. District Judge Robin Rosenberg in MDL NO. 2924 with Magistrate Judge Bruce Reinhart. The initial conference with counsel was held March 20, 2020 at Paul G. Rogers United States Courthouse in West Palm Beach, Florida.
The plaintiffs cite research studies, including a 2016 study from Stanford University. In that study, researchers tested 150 mg of ranitidine in humans and found that after ranitidine intake, urinary NDMA levels increased 400-fold from 110 to 47,600 nanograms (ng). This amount far exceeds the FDA’s set safe daily intake of 96 ng per day. The researchers also noted that levels of NDMA may be much higher because only a small amount of the chemical reaches the urine after it is metabolized.
You may be eligible to recover damages for:
- Medical costs
- Lost wages
- Pain and suffering
- Disability or permanent injury
- Punitive damages
- Wrongful death
The April 1, 2020, the FDA release that ordered withdrawal of all ranitidine drugs, including Zantac, added the following RECOMMENDATION:
- Patients: Patients taking prescription ranitidine should speak with their health care professional about other treatment options before stopping the medicine, as there are multiple drugs approved for the same or similar uses as ranitidine that do not carry the same risks from NDMA. To date, the FDA’s testing has not found NDMA in famotidine (Pepcid), cimetidine (Tagamet), esomeprazole (Nexium), lansoprazole (Prevacid) or omeprazole (Prilosec).
- Consumers: The FDA is also advising consumers taking OTC ranitidine to stop taking any tablets or liquid they currently have, dispose of them properly and not buy more; for those who wish to continue treating their condition, they should consider using other approved OTC products.
- Consumers and Patients: In light of the COVID-19 pandemic, the FDA recommends patients and consumers not take their medicines to a drug take-back location but follow the FDA’s recommended steps which include ways to safely dispose of these medications at home.
In September 2019, the Food and Drug Administration (FDA) released a statement that N-nitrosodimethylamine (NDMA) was detected in at least one manufacturer’s version of ranitidine. Afterwards, some manufacturers voluntarily recalled their own versions of the drug and some of the largest retail stores removed Zantac (ranitidine) from their shelves.
NDMA is classified as a probable human carcinogen and is found in low levels of cigarettes, most foods, and drinking water. The FDA has publicly stated that the levels of NDMA found were “low” and suggested that the risk posed to humans was inconclusive as of now.
There are time limits to retrieve your medical proof of prescription or over the counter drug usage and cancer diagnosis. If you ingested Zantac (ranitidine) on a regular basis and believe the use may have led to cancer of the stomach, colon, intestines, kidneys, bladder or pancreas, contact us now at 1-800-814-4540 or email email@example.com for a free consultation.We understand the health and financial issues you may be facing, so contact us now.
Important information about NDMA impurities in ranitidine:
- The U.S. Food and Drug Administration has requested a manufacturer’s market withdrawal of ranitidine, known commonly by the brand name Zantac. This means ranitidine products will not be available for new or existing prescriptions or over-the-counter (OTC) use in the U.S.
- FDA has found N-nitrosodimethylamine (NDMA) levels in some ranitidine products increase with time and temperature posing a risk to consumers, and therefore the agency has requested the withdrawal of all ranitidine products from the U.S. market.
- Consumers should stop taking any OTC ranitidine they may currently have. Patients taking prescription ranitidine should speak with their health care professional about other treatment options before stopping the medicine. Multiple drugs are approved for the same or similar uses as ranitidine.
- Consumers should dispose of any ranitidine products properly, and not buy more of it including compounded ranitidine.
- To date, FDA’s testing has not found NDMA in products used for similar treatment like famotidine (Pepcid), cimetidine (Tagamet), esomeprazole (Nexium), lansoprazole (Prevacid) or omeprazole (Prilosec).
Free Medical Legal Consultation
We understand the health and financial issues you may be facing, so contact us the speak with a medical legal attorney. There are time limits to retrieve your medical proof of prescription or over the counter drug usage and cancer diagnosis. If you ingested Zantac (ranitidine) on a regular basis and believe the use may have led to cancer of the stomach, colon, intestines, kidneys, bladder or pancreas, contact us now at 1-800-814-4540 or email firstname.lastname@example.org for a free consultation.